{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:33:51Z","timestamp":1793694831571,"version":"4.5.1"},"reference-count":247,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institutes of Health"},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["T32-GM066706"],"award-info":[{"award-number":["T32-GM066706"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.antiviral.2018.11.016","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T20:22:12Z","timestamp":1544214132000},"page":"5-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":275,"special_numbering":"C","title":["The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold"],"prefix":"10.1016","volume":"162","author":[{"given":"Mary K.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0154-3459","authenticated-orcid":false,"given":"Katherine L.","family":"Seley-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.11.016_bib1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1200\/JCO.1983.1.12.750","article-title":"Phase II study of doxifluridine in advanced colorectal adenocarcinoma","volume":"1","author":"Abele","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0277-5379(84)90078-6","article-title":"Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck","volume":"20","author":"Abele","year":"1984","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/jm00401a008","article-title":"Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil","volume":"31","author":"Ajmera","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/jm00401a008","article-title":"Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil","volume":"31","author":"Ajmera","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0277-5379(98)90038-4","article-title":"A phase II study of doxifluridine in patients with advanced breast cancer","volume":"24","author":"Alberto","year":"1988","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.antiviral.2018.11.016_bib6","first-page":"3333","article-title":"Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine","volume":"40","author":"Armstrong","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib7","first-page":"4891","article-title":"Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index","volume":"41","author":"Armstrong","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib8","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1021\/jm00078a006","article-title":"Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum","volume":"36","author":"Azuma","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib9","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1021\/jm00017a023","volume":"38","author":"Azuma","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/07328319708006127","article-title":"Intracellular metabolism and action of an antitumor nucleoside, 2\u2032-C-Cyano-2\u2032-Deoxy-1-\u03b2-d-arabinofuranosylcytosine (CNDAC)","volume":"16","author":"Azuma","year":"1997","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0006-2952(01)00617-7","article-title":"Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)","volume":"61","author":"Azuma","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0026-895X(25)13752-8","article-title":"The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides","volume":"32","author":"Balzarini","year":"1987","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib13","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1016\/S0021-9258(18)83322-1","article-title":"Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds","volume":"264","author":"Balzarini","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/095632020101200405","article-title":"Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues","volume":"12","author":"Barnard","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.antiviral.2018.11.016_bib17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/toxsci\/kfw135","article-title":"Effects of BMS-986094, a guanosine nucleotide analogue, on mitochondrial DNA synthesis and function","volume":"153","author":"Baumgart","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.antiviral.2018.11.016_bib18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/cr040461t","article-title":"Toward a detailed understanding of base excision repair enzymes: transition state and mechanistic analyses of N-glycoside hydrolysis and N-glycoside transfer","volume":"106","author":"Berti","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.11.016_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0005-2787(67)90581-3","article-title":"On the mode of action of 7-deaza-adenosine (tubercidin)","volume":"138","author":"Bloch","year":"1967","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2018.11.016_bib20","first-page":"59","article-title":"Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults","volume":"53","author":"Bodey","year":"1969","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.antiviral.2018.11.016_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"Bohm","year":"2004","journal-title":"Chembiochem"},{"key":"10.1016\/j.antiviral.2018.11.016_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0014-2964(80)90221-2","article-title":"Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine","volume":"16","author":"Bollag","year":"1980","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.antiviral.2018.11.016_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jmb.2004.10.021","article-title":"Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases","volume":"345","author":"Boyer","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/03639040701836636","article-title":"Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability","volume":"34","author":"Brandl","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.antiviral.2018.11.016_bib25","first-page":"1838","article-title":"Studies on the growth inhibition and metabolism of 2'-deoxy-2'-fluorocytidine in cultured human lymphoblasts","volume":"34","author":"Brox","year":"1974","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib27","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/jm0102755","article-title":"Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues","volume":"45","author":"Cappellacci","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib28","doi-asserted-by":"crossref","DOI":"10.1135\/cccc20061088","article-title":"Purine and pyrimidine nucleoside analogs of 3'-C-methyladenosine as antitumor agents","volume":"71","author":"Cappellacci","year":"2006","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.antiviral.2018.11.016_bib29","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib30","article-title":"Robust suppression of viral replication by a nucleoside polymerase inhibitor in chimpanzees infected with hepatitis C virus","volume":"44","author":"Carroll","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib31","first-page":"89","article-title":"Ara-C metabolism: implications for drug resistance and drug interactions","volume":"66","author":"Chabner","year":"1979","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.antiviral.2018.11.016_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0021-9258(18)48487-6","article-title":"Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus","volume":"267","author":"Chen","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib34","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1128\/AAC.00397-10","article-title":"Inhibition of dengue virus by an ester prodrug of an adenosine analog","volume":"54","author":"Chen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib35","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1128\/AAC.00140-10","article-title":"Inhibition of dengue virus RNA synthesis by an adenosine nucleoside","volume":"54","author":"Chen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib36","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JVI.02841-13","article-title":"Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir","volume":"88","author":"Chen","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acsinfecdis.5b00029","article-title":"Bicyclic and tricyclic \u201cexpanded\u201d nucleobase analogues of sofosbuvir: new scaffolds for hepatitis C therapies","volume":"1","author":"Chen","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.016_bib38","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.bmcl.2015.07.086","article-title":"Thiophene-expanded guanosine analogues of Gemcitabine","volume":"25","author":"Chen","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib39","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","article-title":"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides","volume":"22","author":"Cho","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib40","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/jm400201a","article-title":"Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients","volume":"57","author":"Cho","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib41","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/jm00185a002","article-title":"Synthesis of certain [6:5:6] linear tricyclic nucleosides as potential antitumor agents","volume":"23","author":"Chung","year":"1980","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib42","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1021\/jm0502788","article-title":"Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication","volume":"48","author":"Clark","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib50","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/jm00197a010","article-title":"Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides","volume":"22","author":"Cook","year":"1979","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(08)60590-5","article-title":"In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication","volume":"48","author":"Cretton-Scott","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib53","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/15257770701542165","article-title":"Synthesis of 1'-C-fluoromethyladenosine","volume":"26","author":"Damont","year":"2007","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/15257770.2014.917671","article-title":"The 5'-nor aristeromycin analogues of 5'-deoxy-5'-methylthioadenosine and 5'-deoxy-5'-thiophenyladenosine","volume":"33","author":"Das","year":"2014","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"De Clercq","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2005.05.001","article-title":"Antiviral drug discovery and development: where chemistry meets with biomedicine","volume":"67","author":"De Clercq","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.mib.2005.08.010","article-title":"Recent highlights in the development of new antiviral drugs","volume":"8","author":"De Clercq","year":"2005","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.apsb.2012.10.001","article-title":"Milestones in the discovery of antiviral agents: nucleosides and nucleotides","volume":"2","author":"De Clercq","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.antiviral.2018.11.016_bib47","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/acs.jmedchem.5b01157","article-title":"C-nucleosides to Be revisited","volume":"59","author":"De Clercq","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib48","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.11.016_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-540-79086-0_3","article-title":"Antiviral agents acting as DNA or RNA chain terminators","author":"De Clercq","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib56","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1128\/JVI.01207-14","article-title":"Inhibition of enterovirus 71 by adenosine analog NITD008","volume":"88","author":"Deng","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw175","article-title":"Adenosine analog NITD008 is a potent inhibitor of Zika virus","volume":"3","author":"Deng","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.016_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003495-200969020-00002","article-title":"Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides","volume":"69","author":"Deval","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.11.016_bib70","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15257770.2012.707344","article-title":"Synthesis and antiviral properties of novel tetracyclic nucleoside inhibitors of hepatitis C NS5B polymerase","volume":"31","author":"Di Francesco","year":"2012","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib71","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1016\/j.bmc.2012.05.067","article-title":"Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase","volume":"20","author":"Di Francesco","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib60","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1021\/jm040068f","article-title":"Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication","volume":"47","author":"Eldrup","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib61","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1021\/jm030424e","article-title":"Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase","volume":"47","author":"Eldrup","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib62","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.00807-15","article-title":"Nucleoside inhibitors of tick-borne encephalitis virus","volume":"59","author":"Eyer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2016.07.018","article-title":"Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus","volume":"133","author":"Eyer","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01028-17","article-title":"Escape of tick-borne flavivirus from 2'-C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness","volume":"91","author":"Eyer","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib65","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1128\/AAC.02351-13","article-title":"Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug","volume":"58","author":"Feng","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/toxsci\/kfw224","article-title":"Role of mitochondrial toxicity in BMS-986094-induced toxicity","volume":"155","author":"Feng","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.antiviral.2018.11.016_bib67","first-page":"58","article-title":"Antiviral drugs - a short history of their discovery and development","volume":"31","author":"Field","year":"2004","journal-title":"Microbiol. Today"},{"key":"10.1016\/j.antiviral.2018.11.016_bib69","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib72","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/jm048944c","article-title":"Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors","volume":"48","author":"Franchetti","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib73","doi-asserted-by":"crossref","first-page":"39953","DOI":"10.1074\/jbc.M206360200","article-title":"Improving nucleoside diphosphate kinase for antiviral nucleotide analogs activation","volume":"277","author":"Gallois-Montbrun","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.016_bib75","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/13543784.2015.982274","article-title":"Discontinued drugs in 2012 - 2013: hepatitis C virus infection","volume":"24","author":"Gentile","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2018.11.016_bib77","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1081\/NCN-120022615","article-title":"4'-C-methyl-beta-D-ribofuranosyl purine and pyrimidine nucleosides revisited","volume":"22","author":"Griffon","year":"2003","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib78","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1021\/jm990219s","article-title":"Synthesis of fluorosugar analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole as antivirals with potentially increased glycosidic bond stability","volume":"43","author":"Gudmundsson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib79","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0960-894X(95)00256-S","article-title":"Synthesis of 4\u2032-fluoroadenosine as an inhibitor of S-adenosyl-L-homocysteine hydrolase","volume":"5","author":"Guillerm","year":"1995","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2018.11.016_bib81","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.31.11.1849","article-title":"9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity","volume":"31","author":"Hasobe","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib82","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1128\/AAC.00270-09","volume":"53","author":"Hattori","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib83","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/07328319908044851","article-title":"The synthesis of carbocyclic 5\u2032-nor thymidine and an isomer as oligonucleotide monomers","volume":"18","author":"Hegde","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/15257770008033008","article-title":"Carbocyclic 5'-noruridine","volume":"19","author":"Hegde","year":"2000","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib85","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/jm00391a003","article-title":"3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III\/LAV) agents","volume":"30","author":"Herdewijn","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib86","first-page":"722","article-title":"The activity of a new antibiotic, nucleocidin, in experimental infections with Trypanosoma equiperdum","author":"Hewitt","year":"1956","journal-title":"Antibiot. Annu."},{"key":"10.1016\/j.antiviral.2018.11.016_bib87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF01702925","article-title":"Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens","volume":"62","author":"Hiddemann","year":"1991","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib88","first-page":"2816","article-title":"Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse","volume":"33","author":"Ho","year":"1973","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib89","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jo01030a546","article-title":"The monomesylates of 1-(2'-Deoxy-\u03b2-D-lyxofuranosyl)thymine","volume":"29","author":"Horwitz","year":"1964","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib90","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jo01278a070","article-title":"Nucleosides. XI. 2',3'-dideoxycytidine","volume":"32","author":"Horwitz","year":"1967","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib91","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1128\/AAC.38.12.2792","article-title":"Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice","volume":"38","author":"Hostetler","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib92","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2017.06.011","article-title":"4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency","volume":"144","author":"Hotard","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib93","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/nar\/26.9.2237","article-title":"The effect of two antipodal fluorine-induced sugar puckers on the conformation and stability of the Dickerson-Drew dodecamer duplex [d(CGCGAATTCGCG)]2","volume":"26","author":"Ikeda","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib94","first-page":"71","article-title":"Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine","author":"Ishitsuka","year":"1980","journal-title":"Gann"},{"key":"10.1016\/j.antiviral.2018.11.016_bib95","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.016_bib97","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1021\/ja00746a056","article-title":"Synthesis of the nucleoside antibiotic nucleocidin","volume":"93","author":"Jenkins","year":"1971","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.11.016_bib98","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1021\/ja00427a049","article-title":"4'-Substituted nucleosides. 2. synthesis of the nucleoside antibiotic nucleocidin","volume":"98","author":"Jenkins","year":"1976","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.11.016_bib100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2018.11.016_bib101","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","article-title":"Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib102","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(12)70436-9","article-title":"Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib103","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3804.3804","article-title":"Results of a phase I\/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia","volume":"126","author":"Kantarjian","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.11.016_bib104","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7077","article-title":"First report of a phase I\/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia","volume":"33","author":"Kantarjian","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2822.2822","article-title":"Phase I\/II study of DFP-10917 in relapsed\/refractory AML demonstrates efficacy and safety profile suitable for phase III study","volume":"128","author":"Kantarjian","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.11.016_bib106","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S1473-3099(16)30473-X","article-title":"Dengue: knowledge gaps, unmet needs, and research priorities","volume":"17","author":"Katzelnick","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.016_bib107","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.biocel.2008.04.007","article-title":"2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants","volume":"40","author":"Kawamoto","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib109","first-page":"40","article-title":"The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase","volume":"57","author":"Kirby","year":"2011","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)"},{"key":"10.1016\/j.antiviral.2018.11.016_bib110","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1128\/AAC.01703-13","article-title":"Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine","volume":"57","author":"Kirby","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib111","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jfluchem.2006.06.007","article-title":"Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules","volume":"127","author":"Kirk","year":"2006","journal-title":"J. Fluorine Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib112","series-title":"Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection","first-page":"287","author":"Klumpp","year":"2011"},{"key":"10.1016\/j.antiviral.2018.11.016_bib113","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M510195200","article-title":"The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture","volume":"281","author":"Klumpp","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib114","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1074\/jbc.M708929200","article-title":"2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups","volume":"283","author":"Klumpp","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1081\/NCN-120037508","article-title":"Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides","volume":"23","author":"Kohgo","year":"2004","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1248\/cpb.31.175","article-title":"Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors","volume":"31","author":"Kono","year":"1983","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.antiviral.2018.11.016_bib117","doi-asserted-by":"crossref","first-page":"9936","DOI":"10.1021\/ja00051a028","article-title":"Conformation of two 4'-thio-2'-deoxynucleoside analogs studied by 5000-MHz proton NMR spectroscopy and x-ray crystallography","volume":"114","author":"Koole","year":"1992","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.11.016_bib118","first-page":"1519","article-title":"5'-deoxy-5-fluorouridine-a New orally active antitumor agent. comparative activity with 5-fluorouracil, 2'- deoxy-5-fluorouridine and ftorafur against transplant- able tumors in mice and rats","author":"Kramer","year":"1979","journal-title":"Subj. Strain Bibliogr."},{"key":"10.1016\/j.antiviral.2018.11.016_bib119","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/AAC.01521-12","article-title":"Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection","volume":"56","author":"Lalezari","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib120","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00399-10","article-title":"PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication","volume":"54","author":"Lam","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib121","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.016_bib122","doi-asserted-by":"crossref","first-page":"12795","DOI":"10.1021\/acs.jpcb.6b09620","article-title":"Hydrolytic glycosidic bond cleavage in RNA nucleosides: effects of the 2'-hydroxy group and acid-base catalysis","volume":"120","author":"Lenz","year":"2016","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.antiviral.2018.11.016_bib123","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/ar00077a001","article-title":"Dimensional probes of enzyme-coenzyme binding-sites","volume":"15","author":"Leonard","year":"1982","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib124","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1021\/jo00891a021","article-title":"Linear benzoadenine. A stretched-out analog of adenine","volume":"40","author":"Leonard","year":"1975","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib125","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1021\/ja00429a040","article-title":"Defined dimensional changes in enzyme substrates and cofactors. Synthesis of lin-benzoadenosine and enzymatic evaluation of derivatives of the benzopurines","volume":"98","author":"Leonard","year":"1976","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.11.016_bib126","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/bi00611a001","article-title":"Dimensional probes of the enzyme binding sites of adenine nucleotides. biological effects of widening the adenine ring by 2.4 A","volume":"17","author":"Leonard","year":"1978","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.11.016_bib127","first-page":"1198","article-title":"\u00dcber Inosins\u00e4ure. Berichte der deutschen chemischen Gesellschaft","volume":"42","author":"Levene","year":"1909"},{"key":"10.1016\/j.antiviral.2018.11.016_bib128","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1073\/pnas.95.14.7933","article-title":"The stability of the RNA bases: implications for the origin of life","volume":"95","author":"Levy","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.016_bib130","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00749a020","article-title":"Heat-induced depyrimidination of deoxyribonucleic acid in neutral solution","volume":"12","author":"Lindahl","year":"1973","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.11.016_bib131","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jfluchem.2008.06.007","article-title":"Fluorinated nucleosides: synthesis and biological implication","volume":"129","author":"Liu","year":"2008","journal-title":"J. Fluorine Chem."},{"issue":"1","key":"10.1016\/j.antiviral.2018.11.016_bib132","first-page":"179","article-title":"Cytosine arabinoside (NSC-63878)--clinical brochure","volume":"3","author":"Livingston","year":"1968","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.antiviral.2018.11.016_bib133","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.antiviral.2016.03.013","article-title":"In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses","volume":"130","author":"Lo","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib134","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.11.016_bib135","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiw423","article-title":"Current status of dengue therapeutics research and development","volume":"215","author":"Low","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.016_bib136","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0960327115592939","article-title":"Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys","volume":"35","author":"Luo","year":"2016","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib137","doi-asserted-by":"crossref","first-page":"29812","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species","volume":"282","author":"Ma","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib138","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/jm00086a013","article-title":"Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides","volume":"35","author":"Maag","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib142","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1080\/07328319808004726","article-title":"Lessons from the pseudorotational cycle: conformationally rigid AZT carbocyclic nucleosides and their interaction with reverse transcriptase","volume":"17","author":"Marquez","year":"1998","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib143","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/15257779508012407","article-title":"2\u2032-C-Cyano-2\u2032-deoxy-1-\u03b2-D-arabinofuranosylcytosine (CNDAC): a mechanism-based DNA-strand-breaking antitumor nucleoside","volume":"14","author":"Matsuda","year":"1995","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib144","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1021\/jm00113a034","article-title":"Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside","volume":"34","author":"Matsuda","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1021\/jm00106a049","article-title":"Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives","volume":"34","author":"Matsuda","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib146","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chembiol.2008.07.012","article-title":"Deciphering deazapurine biosynthesis: pathway for pyrrolopyrimidine nucleosides toyocamycin and sangivamycin","volume":"15","author":"McCarty","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib147","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1021\/jm950605j","article-title":"Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite","volume":"39","author":"McGuigan","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib148","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm990346o","article-title":"Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base","volume":"42","author":"McGuigan","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib149","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1021\/jm060776w","article-title":"Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives","volume":"49","author":"McGuigan","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib150","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1016\/j.bmcl.2009.05.122","article-title":"The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus","volume":"19","author":"McGuigan","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib151","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1021\/jm1003792","article-title":"Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties","volume":"53","author":"McGuigan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib152","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1016\/j.bmcl.2010.06.094","article-title":"Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus","volume":"20","author":"McGuigan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib153","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cmdc.201600156","article-title":"The ProTides boom","volume":"11","author":"Mehellou","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.antiviral.2018.11.016_bib154","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cmdc.200900289","article-title":"Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells","volume":"4","author":"Mehellou","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.antiviral.2018.11.016_bib155","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib156","first-page":"484","article-title":"Practical synthesis of 1\u2032-substituted Tubercidin C-nucleoside analogs","volume":"53","author":"Metobo","year":"2012"},{"key":"10.1016\/j.antiviral.2018.11.016_bib157","doi-asserted-by":"crossref","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor","volume":"284","author":"Michailidis","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib158","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib159","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0008-6215(83)88357-8","article-title":"Synthesis and properties of 3\u2032-C-methylnucleosides and their phosphoric esters","volume":"124","author":"Mikhailov","year":"1983","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib160","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2',3'-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.016_bib161","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/ja01034a046","article-title":"The structure of nucleocidin. 3. (A new structure)","volume":"91","author":"Morton","year":"1969","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.11.016_bib162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.03.001","article-title":"Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics","volume":"106","author":"Muftuoglu","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib163","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib164","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib165","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/AAC.02350-13","article-title":"Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620","volume":"58","author":"Murakami","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib166","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1128\/AAC.00277-07","article-title":"Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine","volume":"51","author":"Nakata","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib167","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.016_bib168","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/j.bmcl.2012.03.021","article-title":"Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication","volume":"22","author":"Nilsson","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib169","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1021\/jm990050i","article-title":"Nucleosides and nucleotides. 185. Synthesis and biological activities of 4\u2018\u03b1-C-Branched-Chain sugar pyrimidine nucleosides","volume":"42","author":"Nomura","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0040-4039(00)77667-2","article-title":"Synthesis of 4\u2032-cyanothymidine and analogs as potent inhibitors of HIV","volume":"33","author":"O-Yang","year":"1992","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib171","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/tcr.20078","article-title":"2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity","volume":"6","author":"Ohrui","year":"2006","journal-title":"Chem. Rec."},{"key":"10.1016\/j.antiviral.2018.11.016_bib172","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1080\/15257770701545218","article-title":"2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma","volume":"26","author":"Ohrui","year":"2007","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib173","first-page":"71","article-title":"Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil","author":"Ohta","year":"1980","journal-title":"Gann"},{"key":"10.1016\/j.antiviral.2018.11.016_bib174","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","article-title":"A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties","volume":"48","author":"Olsen","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib175","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0277-5379(91)90180-L","article-title":"Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer","volume":"27","author":"van Oosterom","year":"1991","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.antiviral.2018.11.016_bib176","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bmcl.2017.01.040","article-title":"New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors","volume":"27","author":"Orlov","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib177","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1021\/jo00880a018","article-title":"4'-Substituted nucleosides. 3. Synthesis of some 4'-fluorouridine derivatives","volume":"41","author":"Owen","year":"1976","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib178","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0008-6215(00)00089-6","article-title":"Fluorinated nucleosides","volume":"327","author":"Pankiewicz","year":"2000","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib179","volume":"vol. 64","author":"Pankiewicz","year":"1993"},{"key":"10.1016\/j.antiviral.2018.11.016_bib180","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs","volume":"41","author":"Park","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib181","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/07328319208021748","article-title":"Nucleoside analogues as chemotherapeutic agents: a review","volume":"11","author":"Perigaud","year":"1992","journal-title":"Nucleoside Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib182","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP2012","article-title":"Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy","volume":"22","author":"Pertusati","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib183","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.bmcl.2015.05.039","article-title":"Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity","volume":"25","author":"Peters","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib184","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1021\/jm0603623","article-title":"Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine","volume":"49","author":"Pierra","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib185","first-page":"50","article-title":"Cellular pharmacodynamics of anticancer drugs","volume":"20","author":"Plunkett","year":"1993","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib186","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib187","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hep.22593","article-title":"High relapse rate seen at week 72 for patients treated with R1626 combination therapy","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib188","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1021\/ja0498078","article-title":"Conformational properties of shape modified nucleosides--fleximers","volume":"126","author":"Polak","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.11.016_bib189","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3181\/00379727-130-33724","article-title":"A comparative study of the antitumor and antiviral activity of 1-\u03b2-D-Arabinofuranosyl-5-fluorocytosine (FCA) and 1-\u03b2-D-Arabinofuranosylcytosine (CA)","volume":"130","author":"Prince","year":"1969","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2018.11.016_bib190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.antiviral.2015.12.010","article-title":"Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus","volume":"126","author":"Qing","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib191","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1021\/bi0503605","article-title":"Substrate discrimination by the human GTP fucose pyrophosphorylase","volume":"44","author":"Quirk","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.11.016_bib192","doi-asserted-by":"crossref","first-page":"13172","DOI":"10.1021\/bi051288d","article-title":"Identification of catalytic amino acids in the human GTP fucose pyrophosphorylase active site","volume":"44","author":"Quirk","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.11.016_bib193","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-013-0156-3","article-title":"High-dose cytarabine (HD araC) in the treatment of leukemias: a review","volume":"8","author":"Reese","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.antiviral.2018.11.016_bib194","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0006-2952(99)00414-1","article-title":"Polymerization of 2'-fluoro- and 2'-O-methyl-dNTPs by human DNA polymerase alpha, polymerase gamma, and primase","volume":"59","author":"Richardson","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/poc.3318","article-title":"Hydrolytic fitness of N-glycosyl bonds: comparing the deglycosylation kinetics of modified, alternative and native nucleosides","volume":"28","author":"Rios","year":"2015","journal-title":"J. Phys. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib196","volume":"vol. 44","author":"Roberts","year":"2006"},{"key":"10.1016\/j.antiviral.2018.11.016_bib197","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","article-title":"Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C","volume":"48","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib198","first-page":"S98","article-title":"Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting hcv polymerase: results from a phase 1 single dose escalation trial in healthy subjects.: piii-41","volume":"81","author":"Robson","year":"2007","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.antiviral.2018.11.016_bib200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1400","article-title":"Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs","volume":"20","author":"Rondla","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib201","series-title":"Principles of Nucleic Acid Structure","first-page":"9","article-title":"Defining terms for the nucleic acids","author":"Saenger","year":"1984"},{"key":"10.1016\/j.antiviral.2018.11.016_bib202","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.016_bib204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.1987.5.3.419","article-title":"Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma","volume":"5","author":"Schilsky","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib207","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1086\/511310","article-title":"A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs","volume":"195","author":"Schul","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.016_bib208","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1128\/AAC.41.8.1658","article-title":"Synthesis and antitrypanosomal activities of a series of 7-deaza-5'-noraristeromycin derivatives with variations in the cyclopentyl ring substituents","volume":"41","author":"Seley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib209","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/jm9605039","article-title":"(+)-7-Deaza-5\u2018-noraristeromycin as an anti-trypanosomal agent","volume":"40","author":"Seley","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/jm9606148","article-title":"Synthesis and anti-trypanosomal activity of various 8-aza-7-deaza-5'noraristeromycin derivatives","volume":"40","author":"Seley","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib211","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/jm9606148","article-title":"Synthesis and anti-trypanosomal activity of various 8-Aza-7-deaza-5\u2018-noraristeromycin derivatives","volume":"40","author":"Seley","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib212","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1021\/jo970515h","article-title":"A methylated derivative of 5\u2018-noraristeromycin","volume":"62","author":"Seley","year":"1997","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib213","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1080\/07328319708002560","article-title":"A 5\u2032-noraristeromycin enantiomer with activity towards hepatitis B virus","volume":"16","author":"Seley","year":"1997","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib214","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1021\/ol0165443","article-title":"\u201cFleximers\u201d. Design and synthesis of two novel split nucleosides","volume":"3","author":"Seley","year":"2001","journal-title":"Org. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib215","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1021\/jo0255476","article-title":"\u201cFleximers\u201d. design and synthesis of a new class of novel shape-modified nucleosides(1)","volume":"67","author":"Seley","year":"2002","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib216","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0960-894X(03)00331-7","article-title":"Unexpected inhibition of S-adenosyl-L-homocysteine hydrolase by a guanosine nucleoside","volume":"13","author":"Seley","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib217","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ol047895v","article-title":"\u201cMolecular chameleons\u201d. design and synthesis of C-4-substituted imidazole fleximers","volume":"7","author":"Seley","year":"2005","journal-title":"Org. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib218","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/jo048218h","article-title":"\u201cMolecular chameleons\u201d. design and synthesis of a second series of flexible nucleosides","volume":"70","author":"Seley","year":"2005","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib219","series-title":"Flex-nucleoside Analogues","author":"Seley-Radtke","year":"2018"},{"key":"10.1016\/j.antiviral.2018.11.016_bib220","series-title":"Design, Synthesis and Methods of Use of Acyclic Nucleoside Analogues Having Anti-coronavirus Activity","author":"Seley-Radtke","year":"2018"},{"key":"10.1016\/j.antiviral.2018.11.016_bib221","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold","volume":"154","author":"Seley-Radtke","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib222","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/nass\/nrn321","article-title":"Hetero-expanded purine nucleosides. Design, synthesis and preliminary biological activity","author":"Seley-Radtke","year":"2008","journal-title":"Nucleic Acids Symp. Ser. (Oxf.)"},{"key":"10.1016\/j.antiviral.2018.11.016_bib223","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2014.10.009","article-title":"An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation","volume":"112","author":"Shang","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib224","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2018.11.016_bib225","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1128\/AAC.39.11.2555","article-title":"Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells","volume":"39","author":"Shirasaka","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib226","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/jm00007a014","article-title":"Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors","volume":"38","author":"Siddiqi","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib227","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib228","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4155\/fmc.15.96","article-title":"Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor","volume":"7","author":"Sizun","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib229","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.bmcl.2007.02.004","article-title":"Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479","volume":"17","author":"Smith","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/AAC.01004-07","article-title":"Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro","volume":"52","author":"Smith","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib231","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/jm800981y","article-title":"The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib232","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib233","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.05729-11","article-title":"Mechanism of interaction of human mitochondrial DNA polymerase \u03b3 with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity","volume":"56","author":"Sohl","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib234","first-page":"930","article-title":"Kinetics and metabolism of a new fluoropyrimidine, 5\u2032-Deoxy-5-fluorouridine, in humans","volume":"43","author":"Sommadossi","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.11.016_bib235","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/cr9002165","article-title":"C-nucleosides: synthetic strategies and biological applications","volume":"109","author":"Stambask\u00fd","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.11.016_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(08)60069-0","article-title":"Potent antiviral activity of second generation nucleoside inhibitors, IDX102 and IDX184 in HCV-infected chimpanzees","volume":"48","author":"Standring","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib241","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/AAC.48.2.651-654.2004","article-title":"Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine","volume":"48","author":"Stuyver","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib242","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep.27962","article-title":"4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus","volume":"62","author":"Takamatsu","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.11.016_bib243","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0304-3835(92)90024-P","article-title":"Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors","volume":"64","author":"Tanaka","year":"1992","journal-title":"Cancer Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib244","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3762\/bjoc.14.65","article-title":"Recent advances in synthetic approaches to C-nucleosides","volume":"14","author":"Temburnikar","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib245","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0959-8049(05)80055-3","article-title":"Interactions of interferon-\u03b12a with 5\u2032-deoxy-5-fluorouridine in colorectal cancer cells in vitro","volume":"28","author":"Tevaearai","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.antiviral.2018.11.016_bib246","first-page":"716","article-title":"Nucleocidin, a new antibiotic with activity against trypanosomes","author":"Thomas","year":"1956","journal-title":"Antibiot. Annu."},{"key":"10.1016\/j.antiviral.2018.11.016_bib247","first-page":"738","article-title":"1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus","volume":"11","author":"Toniutto","year":"2008","journal-title":"IDrugs"},{"key":"10.1016\/j.antiviral.2018.11.016_bib248","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/095632029500600605","article-title":"Zalcitabine (DDC) phosphorylation and drug-interactions","volume":"6","author":"Veal","year":"1995","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib249","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/AAC.01335-10","article-title":"INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties","volume":"55","author":"Vernachio","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib250","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1271\/bbb.57.1433","article-title":"Synthesis of 4'-C-methylnucleosides","volume":"57","author":"Waga","year":"1993","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib251","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/07328319608002385","article-title":"Synthesis and biological evaluation of 4\u2032-C-methyl nucleosides","volume":"15","author":"Waga","year":"1996","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.11.016_bib252","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib253","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.11.016_bib254","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.bmc.2012.03.004","article-title":"Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues","volume":"20","author":"Wauchope","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib255","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1055\/s-0032-1316791","article-title":"Synthetic routes to a series of proximal and distal 2'-deoxy fleximers","volume":"44","author":"Wauchope","year":"2012","journal-title":"Synthesis (Stuttg.)"},{"key":"10.1016\/j.antiviral.2018.11.016_bib256","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfluchem.2012.06.026","article-title":"Synthesis and applications of fluorinated nucleoside analogues","volume":"143","author":"Wojtowicz-Rajchel","year":"2012","journal-title":"J. Fluorine Chem."},{"key":"10.1016\/j.antiviral.2018.11.016_bib257","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1021\/acschembio.5b00263","article-title":"Nucleotide sugar pucker preference mitigates excision by HIV-1 RT","volume":"10","author":"Yamada","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.antiviral.2018.11.016_bib258","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.bmcl.2017.04.069","article-title":"Flex-nucleoside analogues - novel therapeutics against filoviruses","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib259","article-title":"Synthesis and biological evaluation of novel flexible nucleoside analogues that inhibit flavivirus replication in vitro","author":"Yates","year":"2018","journal-title":"In preparation"},{"key":"10.1016\/j.antiviral.2018.11.016_bib260","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1128\/AAC.04779-14","article-title":"Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors","volume":"59","author":"Yeo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib261","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Yin","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.016_bib262","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1016\/j.bmcl.2011.09.034","article-title":"Synthesis of purine modified 2'-C-methyl nucleosides as potential anti-HCV agents","volume":"21","author":"Zhang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib263","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/AAC.01101-10","article-title":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects","volume":"55","author":"Zhou","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.016_bib264","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.bmcl.2013.03.077","article-title":"Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors","volume":"23","author":"Zhou","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.11.016_bib265","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/15257770.2013.771187","article-title":"\u201cReverse\u201d carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors","volume":"32","author":"Zimmermann","year":"2013","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.016_bib266","doi-asserted-by":"crossref","first-page":"21200","DOI":"10.3390\/molecules191221200","article-title":"Design and synthesis of a series of truncated neplanocin fleximers","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2018.11.016_bib267","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004695","article-title":"The Viral polymerase Inhibitor 7-deaza-2'-C-Methyladenosine is a potent inhibitor of in vitro zika virus replication and delays disease progression in a robust mouse infection model","volume":"10","author":"Zmurko","year":"2016","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:46Z","timestamp":1759062466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":247,"alternative-id":["S0166354218306375"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.016","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}